Skip to main content
. Author manuscript; available in PMC: 2014 Feb 19.
Published in final edited form as: Am J Kidney Dis. 2013 May 16;62(2):201–213. doi: 10.1053/j.ajkd.2013.03.018
  • 3.1

    We recommend that non-diabetic adults with CKD ND and urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office BP is consistently >140 mm Hg during systole or >90 mm Hg during diastole be treated with BP-lowering drugs to maintain a BP that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. (1B)

  • 3.2

    We suggest that non-diabetic adults with CKD ND and with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office BP is consistently >130 mm Hg during systole or >80 mm Hg during diastole be treated with BP-lowering drugs to maintain a BP that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. (2D)

  • 3.3

    We suggest that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office BP is consistently >130 mm Hg during systole or >80 mm Hg during diastole be treated with BP-lowering drugs to maintain a BP that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. (2C)

  • 3.4

    We suggest that an ARB or ACE-I be used as first-line therapy in non-diabetic adults with CKD ND and with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with BP-lowering drugs is indicated. (2D)

  • 3.5

    We recommend that an ARB or ACE-I be used as first-line therapy in non-diabetic adults with CKD ND and with urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with BP-lowering drugs is indicated. (1B)

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor(s); ARB, angiotensin-receptor blocker; BP, blood pressure; CKD, chronic kidney disease; ND, non– dialysis-dependent.

*

The guideline notes that “[a]pproximate equivalents for albumin excretion rate per 24 hours— expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results” are provided in the Table 1 of Chapter 1 of the guideline.

Reproduced with permission of KDIGO from the KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.1